Business EconomyPosted at: Nov 2 2026 7:19PM


Granules India Q2 net profit rises 39 pc to Rs 181.8 cr

Hyderabad, Nov 2 (UNI) Hyderabad-based pharmaceutical company Granules India Ltd on Monday reported a 39 per cent year-on-year increase in consolidated net profit at Rs 181.8 crore for the second quarter ended September 30, 2026, compared to Rs 130.6 crore in the corresponding quarter last fiscal.
Revenue from operations rose 20 per cent to Rs 1,560 crore from Rs 1,297 crore in Q2 FY26, while EBITDA increased 21 per cent to Rs 337.6 crore from Rs 278.2 crore, the company said in a release.
Profit before tax (PBT) grew 38 per cent to Rs 243.4 crore against Rs 175.9 crore in the year-ago quarter.
EBITDA margin stood at 22 per cent, compared to 21 per cent a year earlier.
On a sequential basis, revenue increased six per cent from Rs 1,476.8 crore in Q1 FY27, while net profit rose one per cent from Rs 180 crore.
Finished dosages contributed 73 per cent of the company's revenue during the quarter, followed by Active Pharmaceutical Ingredients (APIs) at 13 per cent, Pharmaceutical Formulation Intermediates (PFIs) at 10 per cent and Peptides CDMO at three per cent.
North America accounted for 72 per cent of the revenue, while Europe contributed 16 per cent.
The company reported a Return on Capital Employed (ROCE) of 17.6 per cent.
Granules India closed the quarter with a net cash position of Rs 828 crore, compared to net debt of Rs 101.2 crore at the end of Q1 FY27.
Commenting on the results, Chairman and Managing Director Dr Krishna Prasad Chigurupati said quarterly revenue crossed Rs 1,500 crore, with EBITDA at Rs 338 crore, despite higher input and logistics costs arising from tensions in West Asia.
He said cost pressures were expected to persist and the company was working with customers to manage them. Granules India filed two potential first-to-file Abbreviated New Drug Applications (ANDAs) during the first half of FY27, taking the total to three.
The company would continue to focus on complex generics and peptide CDMO, while investing in research and development, manufacturing and quality with the balance proceeds received from warrants, he added.
Dr Chigurupati also said the US FDA audit at the company's Gagillapur facility had recently concluded. The inspection progressed constructively, and the observations were of a nature that the company believed could be addressed through its responses and corrective and preventive actions.
UNI KNR BM
Tags: #Granules India Q2 net profit rises 39 pc to Rs 181.8 cr
More News

Adani-owned Ambuja Cements firms up its growth phase with 30 MTPA expansion plan

02 Nov 2026 | 8:42 PM

Mumbai, Nov 2 (UNI) Adani-owned Ambuja Cements Ltd officially announced here today that it plans to add new greenfield and brownfield projects, in order to increase 30 (Million Tonnes Per Annum) MTPA of cement capacity across key markets, backed by a growth capital expenditure programme of approximately Rs 14,500 crore.

see more..

Dr Reddy’s gets tentative USFDA nod for twice-yearly HIV prevention injection

02 Nov 2026 | 8:35 PM

Hyderabad, Nov 2 (UNI) Dr. Reddy’s Laboratories Ltd has received tentative approval from the US Food and Drug Administration (USFDA) for its twice-yearly injectable lenacapavir, paving the way for expanded access to HIV prevention in 120 countries outside the United States.

see more..

Stock markets close with gains, Sensex rally over 1200 points

02 Nov 2026 | 7:56 PM

New Delhi, Nov 2 (UNI) Indian stock markets on Monday ended higher on the third straight session. Benchmark Nifty crossed the 23,300 mark supported by strong buying in heavyweight stocks.

see more..

Granules India Q2 net profit rises 39 pc to Rs 181 8 cr

02 Nov 2026 | 7:19 PM

Hyderabad, Nov 2 (UNI) Hyderabad-based pharmaceutical company Granules India Ltd on Monday reported a 39 per cent year-on-year increase in consolidated net profit at Rs 181.8 crore for the second quarter ended September 30, 2026, compared to Rs 130.6 crore in the corresponding quarter last fiscal.

see more..

Ambuja Cements plans 2 9 MTPA grinding unit in Jharkhand's Godda

02 Nov 2026 | 7:05 PM

Ranchi, Nov 2 (UNI) Ambuja Cements Limited has proposed setting up a 2.9 million tonnes per annum (MTPA) cement grinding unit at Godda in Jharkhand as part of its Rs 14,500 crore expansion programme to increase its overall cement capacity to 155 MTPA by FY30.

see more..